Although gonadotropin-releasing hormone agonists (GnRHa) have been used in the therapy of the endocrine-dependent cancers, their biological mechanism remained obscure. We have studied the roles of mitogen-activated protein kinase family in the antiproliferative effect of GnRHa on the Caov-3 human ovarian cancer cell line. Reverse transcription-PCR assays confirmed mRNA for GnRH receptor in Caov...

Methods Twenty boys with ICPP were treated with GnRHa for (20. 0 ± 6. 1) months. At the beginning of therapy, mean chronological age and bone age was(11. 4 ± 1. 0) years and(13. 0 ± 0. 4) years, respectively. GnRHa was discontinued when the boys reached the chronological age and bone age of (13. 2 ± 1. 1) years and (13. 7 ± 0. 6) years, respectively. At the conclusion of the study, all the boys...

The aim of this study was to investigate the effects of different Luteinizing hormone (LH) and steroid hormones levels on LH receptor (LHR) expression in the hippocampal cells. Rats (24 males and 24 females) were assigned to four groups: one control and three experimental [gonadectomy (GDX), gonadectomy + gonadotropin releasing hormone analogue (GDX+GnRHa) and GDX+GnRHa+estradiol (E2) or testos...

Objective: To test the efficacy of GnRHa administered before and during combination chemotherapy in ovarian function preservation for breast cancer women. Patient(s): In this prospective, randomized, study, sixty three patients younger than or equal to 45y old with non metastatic unilateral adenocarcinoma of the breast who had undergone modified radical mastectomy or breast-conserving surgery w...

PURPOSE There is controversy surrounding the growth outcomes of treatment with gonadotropin-releasing hormone agonist (GnRHa) in central precocious puberty (CPP). We analyzed height preservation after treatment with GnRHa with and without growth hormone (GH) in girls with CPP. METHODS We reviewed the medical records of 82 girls with idiopathic CPP who had been treated with GnRHa at Severance ...

Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50% of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has th...

PURPOSE Gonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and insulin resistance during the first year of GnRHa treatment for CPP. METHODS Patient group included 83 girls (aged 7.0-8.9 years) with developed breasts and a peak luteinizin...

PURPOSE Treatment with cyclophosphamide (CYC) confers up to a 40% risk of ovarian failure in women of reproductive age. The use of GnRH agonists (GnRHa) to preserve ovarian function has been investigated in several small studies. We performed a systematic review of studies examining whether a GnRHa administered during chemotherapy is protective of ovarian function and fertility. METHODS We se...

During the in vitro fertilization treatment, human chorionic gonadotrophin (hCG) is routinely used as a substitute for natural endogenous LH surge during final stage of oocyte maturation. However, it does not provide FSH observed mid-cycle cycle. To date, whether can improve quality and pregnancy outcomes remains unknown. Randomized controlled trials comparing following four trigger methods to ...